Trials / Recruiting
RecruitingNCT07100171
Evaluation of GM101 Injection in Patients With Parkinson's Disease
A Single-Center, Open-Label, Single-Arm Exploratory Study Evaluating GM101 Injection in Patients With Mid-to-Late Stage Parkinson's Disease
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Genemagic Biosciences Co., Ltd · Industry
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety of GM101 in participants with Parkinson's disease (PD)
Detailed description
We utilize adeno-associated viruses (AAVs) to deliver gene to reprogram astrocytes in the putamen into dopaminergic neurons to treat patients with Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biological: GM101 | Neurosurgical delivery of GM101 to the putamen |
Timeline
- Start date
- 2025-05-29
- Primary completion
- 2027-02-17
- Completion
- 2030-02-17
- First posted
- 2025-08-03
- Last updated
- 2025-08-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07100171. Inclusion in this directory is not an endorsement.